Pharmaceutical News

RSS

Methylene blue emerges as an adjunct in septic shock

Recent evidence suggests methylene blue may help reduce vasopressor needs and ICU stays in septic shock, but current data do not support replacing standard therapies. Further research is needed to clarify its optimal dosing, timing, and patient selection for best outcomes.

26 Jun 2025

NANOSPRESSO device brings precision medicine to hospital pharmacies

A new gene therapy delivery device could let hospital pharmacies make personalized nanomedicines to order.

26 Jun 2025

One in six cancer medications fails safety standards in sub-Saharan Africa

Serious quality defects were found in a significant number of cancer medications from sub-Saharan Africa, according to new research from the University of Notre Dame.

26 Jun 2025

Tirzepatide rewires appetite and slashes calorie intake in new obesity trial

A 6-week randomized trial found that tirzepatide significantly reduced energy intake, appetite, and cravings in adults with overweight or obesity, outperforming liraglutide and placebo. Brain imaging revealed that tirzepatide also lowered neural responses to high-fat, high-sugar food cues, offering mechanistic insight into its potent weight-loss effects.

25 Jun 2025

How a novel reaction in E. coli helps recycle plastic into paracetamol

Researchers have demonstrated that E. coli can perform a biocompatible Lossen rearrangement, enabling phosphate-catalysed conversion of synthetic substrates into valuable compounds. This approach allows engineered bacteria to upcycle PET plastic waste into paracetamol, highlighting a novel intersection of chemistry and biotechnology.

24 Jun 2025

Once-monthly obesity injection shows double-digit weight loss in major clinical trial

Researchers found that once-monthly maridebart cafraglutide led to substantial weight loss and improved glycemic control in adults with obesity, with or without diabetes, in a phase 2 randomized trial. The drug demonstrated an acceptable safety profile and supports further study in phase 3 trials.

24 Jun 2025

Diabetes drug semaglutide shows promise in reducing dementia risk

Researchers at the Case Western Reserve School of Medicine have found that semaglutide, a popular diabetes and weight-loss drug, may lower the risk of dementia in people with type 2 diabetes (T2D).

24 Jun 2025

Cagrilintide and semaglutide together drive record weight loss in global trial

A 68-week phase 3 trial found that coadministered cagrilintide and semaglutide led to significant and clinically meaningful weight loss in adults with obesity but no diabetes. The combination outperformed either drug alone and improved multiple cardiometabolic health markers.

23 Jun 2025

Amycretin delivers unprecedented weight loss in early trial for obesity treatment

Once-weekly amycretin, a novel peptide activating GLP-1, amylin, and calcitonin receptors, produced rapid, substantial, and sustained weight loss in adults with overweight or obesity during a phase 1b/2a trial. The treatment was generally well tolerated, with mostly mild to moderate gastrointestinal side effects, supporting further investigation in larger, longer studies.

23 Jun 2025

New oral drug shows promise for type 2 diabetes and obesity without side effects

Lower blood sugar and increased fat burning – without negatively affecting appetite or muscle mass. These are some of the most promising effects of a new potential drug treatment for people with type 2 diabetes and obesity, according to a new study published in the journal Cell by researchers from Karolinska Institutet and Stockholm University.

23 Jun 2025

Aspirin lowers diabetes risk during COVID-19, but not without side effects

A large real-world Italian cohort study found that daily low-dose aspirin use significantly lowered the risk of developing type 2 diabetes, especially during the COVID-19 pandemic. The protective effect appears linked to aspirin’s anti-inflammatory properties, though bleeding risks require caution.

19 Jun 2025

Why Alzheimer’s DNA tests don’t treat all populations equally

A major global study tested whether European-derived polygenic risk scores (PGS) for Alzheimer’s disease can predict risk across diverse populations. While PGS performed well in many groups, it was less accurate in individuals of sub-Saharan African and Indian ancestry, highlighting the urgent need for more inclusive genetic data.

19 Jun 2025

Full tumor DNA sequencing becomes standard for children with cancer

Readouts of the full DNA of children with cancer at diagnosis have been implemented as the standard of care in a European first.

19 Jun 2025

A revolutionary drug for extreme hunger offers clues to obesity’s complexity

Ali Foley Shenk still remembers the panic when her 10-year-old son, Dean, finished a 20-ounce box of raisins in the seconds the cupboard was left unlocked. They rushed to the emergency room, fearing a dangerous bowel impaction.

16 Jun 2025

Non-prescribed ketamine use rises sharply across the UK

The rise in non-prescribed ketamine use across the UK in recent years is a cause for concern, say doctors in The BMJ today.

12 Jun 2025

Rutgers study challenges FDA warning on antiseizure drug

Rutgers Health researchers found that lamotrigine, a widely prescribed antiseizure medication, to be safe in older adults with epilepsy, contrary to a safety warning by the Food and Drug Administration (FDA).

11 Jun 2025

Chikungunya vaccine could stop millions of infections worldwide, study finds

A landmark global modeling study reveals that more than 2.8 billion people in 104 countries are at risk of chikungunya, with up to 35 million infections annually. Strategic deployment of the IXCHIQ vaccine could prevent thousands of infections and deaths each year.

11 Jun 2025

AMA endorses resolution to expand access to anti-obesity medications

The American Medical Association (AMA) House of Delegates today passed the Endocrine Society's resolution to improve access to anti-obesity medications.

11 Jun 2025

Large cohort study reassures on mRNA vaccine safety for early pregnancies

A large prospective cohort study in Germany found no statistically significant increase in major birth defects following first trimester mRNA COVID-19 vaccination. While slightly higher rates of some anomalies were observed in vaccinated pregnancies, no consistent patterns or causal links emerged.

11 Jun 2025

Psilocybin rewires the brain for weeks, study finds

Psilocybin induces consistent and sustained changes in brain network connectivity, particularly between the hippocampus and default mode network, as shown using high-resolution fMRI in healthy adults. These neural effects, distinct from those produced by methylphenidate, may underlie the drug’s psychological benefits and were reproducible within individuals over time.

10 Jun 2025